Search
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: BELSOMRA® 15 MG, BELSOMRA® 10 MGNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalEfinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Synonyms: (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanolCategories: Heterocyclic Compounds, 1-RingDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLNetupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamideCategories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Products: VIMIZIM® 1MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓNAtosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAlthough initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form.
Products: EVERPREM® SOLUCIÓN PARA INFUSIÓN 6.75 MG/0.9 ML, TRACTOCILE 37.5 MG/ 5 ML CONCENTRADO PARA SOLUCION POR INFUSIONCefminox
go.drugbank.com/drugs/DB09062ExperimentalCefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.
Categories: Heterocyclic Compounds, 2-RingVortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalreceptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: KELAC 5 MG, KELAC® 10MGTrimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … [L33015] Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.
Synonyms: 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochlorideCategories: Heterocyclic Compounds, 1-Ring